| 1 |
郑荣寿, 孙可欣, 张思维, 等. 2015 年中国恶性肿瘤流行情况分析 [J]. 中华肿瘤杂志, 2019, 41(1): 19-28.
|
| 2 |
Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer (Primer) [J]. Nat Rev Dis Primers, 2019, 5(1): 66.
|
| 3 |
Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene [J]. Science, 1987, 235(4785): 177-182.
|
| 4 |
Voduc KD, Cheang MC, Tyldesley S, et al. Breast cancer subtypes and the risk of local and regional relapse [J]. J Clin Oncol, 2010, 28(10): 1684-1691.
|
| 5 |
Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer [J]. Arch Pathol Lab Med, 2007, 131(1): 18-43.
|
| 6 |
Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical oncology/College of American Pathologists clinical practice guideline update [J]. J Clin Oncol, 2013, 31(31): 3997-4013.
|
| 7 |
Wolff AC, Hammond ME, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update [J]. J Clin Oncol, 2018, 36(20): 2105-2122.
|
| 8 |
《乳腺癌HER2检测指南(2019版)》编写组. 乳腺癌HER2检测指南(2019版) [J]. 中华病理学杂志, 2019, 48(3): 169-175.
|
| 9 |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会乳腺癌诊疗指南2021 [M]. 北京: 人民卫生出版社, 2021: 3.
|
| 10 |
Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer [J]. N Engl J Med, 2011, 365(14): 1273-1283.
|
| 11 |
Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31 [J]. J Clin Oncol, 2011, 29(25): 3366-3373.
|
| 12 |
Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial [J]. Lancet, 2013, 382(9897): 1021-1028.
|
| 13 |
Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer [J]. N Engl J Med, 2005, 353(16): 1673-84.
|
| 14 |
Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort [J]. Lancet, 2010, 375(9712): 377-384.
|
| 15 |
Untch M, Loibl S, Bischoff J, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial [J]. Lancet Oncol, 2012, 13(2): 135-144.
|
| 16 |
Guarneri V, Frassoldati A, Bottini A, et al. Preoperative chemotherapy plus Trastuzumab, Lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase Ⅱ CHER-LOB study [J]. J Clin Oncol, 2012, 30(16): 1989-1995.
|
| 17 |
De Azambuja E, Holmes AP, Piccart-Gebhart M, et al. Lapatinib with Trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response [J]. Lancet Oncol, 2014, 15(10): 1137-1146.
|
| 18 |
Clavarezza M, Puntoni M, Gennari A, et al. Dual block with lapatinib and trastuzumab versus single-agent trastuzumab combined with chemotherapy as neoadjuvant treatment of HER2-positive breast cancer: a meta-analysis of randomized trials [J]. Clin Cancer Res, 2016, 22(18): 4594-4603.
|
| 19 |
Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial [J]. Lancet Oncol, 2012, 13(1): 25-32.
|
| 20 |
Shao Z, Pang D, Yang H, et al. Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: the PEONY phase 3 randomized clinical trial [J]. JAMA Oncol, 2020, 6(3): e193692.
|
| 21 |
Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus Trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase Ⅱ cardiac safety study (TRYPHAENA) [J]. Ann Oncol, 2013, 24(9): 2278-2284.
|
| 22 |
Van Ramshorst MS, Van der Voort A, Van Werkhoven ED, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial [J]. Lancet Oncol, 2018, 19(12): 1630-1640.
|
| 23 |
Hurvitz SA, Martin M, Symmans WF, et al. Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE) [J]. J Clin Oncol, 2016, 34(15_suppl): 500.
|
| 24 |
Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years' follow-up of Trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial [J]. Lancet, 2017, 389(10075): 1195-1205.
|
| 25 |
Von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer [J]. N Engl J Med, 2019, 380(7): 617-628.
|